Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
28 11 2022
Historique:
received: 12 07 2022
accepted: 18 11 2022
entrez: 28 11 2022
pubmed: 29 11 2022
medline: 1 12 2022
Statut: epublish

Résumé

Despite beneficial effects in acute heart failure, the full therapeutic potential of recombinant relaxin-2 has been hampered by its short half-life and the need for intravenous administration limiting its use to intensive care units. A multiparametric optimization of the relaxin B-chain led to the identification of single chain lipidated peptide agonists of RXFP1 like SA10SC-RLX with subcutaneous bioavailability and extended half-life. SA10SC-RLX has sub nanomolar activity on cells expressing human RXFP1 and molecular modeling associated with the study of different RXFP1 mutants was used to decipher the mechanism of SA10SC-RLX interaction with RXFP1. Telemetry was performed in rat where SA10SC-RLX was able to engage RXFP1 after subcutaneous administration without tachyphylaxis after repeated dosing. Renal blood flow was then used as a translational model to evaluate RXFP1 activation. SA10SC-RLX increased renal blood flow and decreased renal vascular resistance in rats as reported for relaxin in humans. In conclusion, SA10SC-RLX mimics relaxin activity in in vitro and in vivo models of acute RXFP1 engagement. SA10SC-RLX represents a new class of long-lasting RXFP1 agonist, suitable for once daily subcutaneous administration in patients and potentially paving the way to new treatments for chronic fibrotic and cardiovascular diseases.

Identifiants

pubmed: 36443381
doi: 10.1038/s41598-022-24716-2
pii: 10.1038/s41598-022-24716-2
pmc: PMC9705314
doi:

Substances chimiques

Relaxin 9002-69-1
RXFP1 protein, human 0
Receptors, Peptide 0
Receptors, G-Protein-Coupled 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20435

Subventions

Organisme : National Health and Medical Research Council of Australia Research Fellowship
ID : 1135837

Informations de copyright

© 2022. The Author(s).

Références

N Engl J Med. 2019 Aug 22;381(8):716-726
pubmed: 31433919
N Engl J Med. 2019 Feb 7;380(6):539-548
pubmed: 30415601
Br J Pharmacol. 2017 May;174(10):1002-1014
pubmed: 27590257
J Biol Chem. 2006 Nov 17;281(46):34942-54
pubmed: 16963451
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Nat Commun. 2016 Apr 18;7:11344
pubmed: 27088579
Br J Pharmacol. 2016 Feb;173(3):484-96
pubmed: 26493539
J Am Coll Cardiol. 2013 Jan 15;61(2):196-206
pubmed: 23273292
J Chem Inf Comput Sci. 2004 May-Jun;44(3):1162-76
pubmed: 15154786
J Clin Invest. 2001 Jun;107(11):1469-75
pubmed: 11390429
Bioconjug Chem. 2019 Jan 16;30(1):83-89
pubmed: 30543420
Front Endocrinol (Lausanne). 2013 Nov 11;4:171
pubmed: 24273532
Mol Immunol. 1999 Apr;36(6):373-86
pubmed: 10444001
J Endocr Soc. 2017 Jun;1(6):712-725
pubmed: 28825052
Endocrinology. 2004 Oct;145(10):4712-20
pubmed: 15256493
Br J Pharmacol. 2017 May;174(10):962-976
pubmed: 27250825
Br J Pharmacol. 2017 May;174(10):921-932
pubmed: 28009437
Circ Res. 1994 Mar;74(3):537-41
pubmed: 8118961
J Biol Chem. 2000 Nov 17;275(46):36143-51
pubmed: 10945997
Am J Physiol Regul Integr Comp Physiol. 2018 Feb 1;314(2):R147-R152
pubmed: 29046312
J Biol Chem. 2013 Sep 27;288(39):28138-51
pubmed: 23926099
J Biol Chem. 2005 Apr 8;280(14):14051-6
pubmed: 15695505
Nat Rev Cardiol. 2015 Apr;12(4):220-9
pubmed: 25666406
J Card Fail. 2009 Apr;15(3):182-90
pubmed: 19327619
MAbs. 2012 Mar-Apr;4(2):243-55
pubmed: 22453096
Biometrics. 1986 Sep;42(3):575-82
pubmed: 3567290
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1403-8
pubmed: 15178555
Chem Sci. 2016 Jun 1;7(6):3805-3819
pubmed: 30155023
Mol Cell Endocrinol. 2019 May 1;487:24-33
pubmed: 30592984
J Am Soc Nephrol. 2006 Nov;17(11):2960-1
pubmed: 17035603
J Clin Invest. 1999 Feb;103(4):525-33
pubmed: 10021461
Hypoxia (Auckl). 2018 May 22;6:11-22
pubmed: 29862306
Br J Pharmacol. 2015 Feb;172(4):1005-19
pubmed: 25297987
J Clin Pharmacol. 2015 Apr;55(4):415-22
pubmed: 25408331
Nucleic Acids Res. 2012 Jan;40(Database issue):D370-6
pubmed: 21890895
J Biol Chem. 2014 Dec 12;289(50):34938-52
pubmed: 25352603
Nephrol Dial Transplant. 2012 Jun;27(6):2190-7
pubmed: 22086971
J Am Soc Nephrol. 2006 Nov;17(11):3192-7
pubmed: 17035617
J Med Chem. 2021 Feb 25;64(4):2139-2150
pubmed: 33555858
Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F70-F80
pubmed: 28978531
Sci Rep. 2017 Jun 7;7(1):2968
pubmed: 28592882
FASEB J. 2005 Sep;19(11):1525-7
pubmed: 16009702
Ann N Y Acad Sci. 2009 Apr;1160:304-12
pubmed: 19416209
Bioorg Med Chem Lett. 2013 Jul 15;23(14):4011-8
pubmed: 23743288
Br J Pharmacol. 2012 Mar;165(6):1644-1658
pubmed: 21557732

Auteurs

Stephane Illiano (S)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France. stephane.illiano@irsn.fr.
IRSN, B.P. 17, 92262, Fontenay-Aux-Roses Cedex, France. stephane.illiano@irsn.fr.

Bruno Poirier (B)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Claire Minoletti (C)

Integrated Drug Discovery, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Olivier Pasquier (O)

DMPK France, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Laurence Riva (L)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Xavier Chenede (X)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Isabelle Menguy (I)

Integrated Drug Discovery, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Michel Guillotel (M)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Philippe Prigent (P)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Stéphane Le Claire (S)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Florence Gillot (F)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Gilbert Thill (G)

Translational Science, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

François Lo Presti (F)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Alain Corbier (A)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Jean-Christophe Le Bail (JC)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Patrick Grailhe (P)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Edith Monteagudo (E)

Peptides and Small Molecules R&D Department, ≠DMPK, and Structural Biology IRBM Spa, Via Pontina Km 30 600, 00 071, Pomezia, RM, Italy.

Raffaele Ingenito (R)

Peptides and Small Molecules R&D Department, ≠DMPK, and Structural Biology IRBM Spa, Via Pontina Km 30 600, 00 071, Pomezia, RM, Italy.

Elisabetta Bianchi (E)

Peptides and Small Molecules R&D Department, ≠DMPK, and Structural Biology IRBM Spa, Via Pontina Km 30 600, 00 071, Pomezia, RM, Italy.

Christophe Philippo (C)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Olivier Duclos (O)

Integrated Drug Discovery, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Sergio Mallart (S)

Integrated Drug Discovery, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.
Structural biology and chemistry, Institut Pasteur, PARIS, France.

Ross Bathgate (R)

Florey Institute of Neuroscience and Mental Health and Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC, 3052, Australia.

Philip Janiak (P)

Cardio-Vascular and Metabolism, Sanofi R&D, 1 avenue Pierre Brossolette, 91385, Chilly-Mazarin, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH